Discover the Scientific Programme
View the full programme
Session 1: Epidemiology, disease modifiers, and models of care
- Current epidemiology and future trends
- Nutrition, alcohol, and environmental toxins as (co-) factors of NAFLD
- Case finding, screening of risk populations, and clinical algorithms
- Evolving models of care: How will the future look?
- Panel discussion
Session 2: New technologies for better stratification of patients
- Disease phenotyping by metabolomics and lipidomics
- Are polygenic risk scores ready for clinical routine?
- Machine learning approaches relating to NAFLD
- Digital pathology and image analysis
- Panel discussion
Session 3: Non-invasive fibrosis markers : Present and future
- Serum-based biomarkers: Staging and treatment response
- Imaging biomarkers: Staging and treatment response
- Panel discussion: The future of liver biopsy
Session 4: Mechanisms of disease progression and implications for therapeutic targets
- Advances in understanding intrinsic mechanisms in NAFLD: metabolism
- Advances in understanding intrinsic mechanisms in NAFLD: inflammation, fibrosis
- Organ cross-talk as a NAFLD modulator: gut and adipose tissue
- Organ cross-talk as a NAFLD modulator: brain and endocrine signals
- Panel discussion
Session 5: New approaches to lifestyle modification – case-based discussion
- Case presentation
- Short presentations from different disciplines:
- Nutrition & app specialist
- Exercise trainer
- Bariatric surgeon
- Hepatology - Panel discussion
Session 6: Personalized medicine in 2032 – how will it look like?
- Sexual dimorphism: the overlooked obvious?
- Gut microbiota as a target for personalized NAFLD interventions
- Gene silencing by siRNA treatment
- Biomarkers for personalized NAFLD medicine – thinking outside the box
- Panel discussion
Session 7: Overlooked issues in clinical trials
- Cardiovascular safety
- Extrahepatic malignancies
- Alcohol misuse, depression, anxiety
- The patient’s perspective
- Panel discussion
Session 8: How do pharmacological treatments of comorbidities affect NAFLD – case-based discussion
- Case presentation
- Short presentations from different disciplines:
- Obesity
- Dyslipidemia
- Diabetes
- Hypothyreoidism - Panel discussion
Session 9: Why do trials fail? Industry perspective & academia perspective
- Selonsertib
- Cenicriviroc
- Elafibranor
- Panel discussion: Consequences for future trials?
Session 10: Clinical trial landscape in 2022
- Phase 1-2 drug candidates for non-cirrhotic NASH
- Phase 3 non-cirrhotic NASH
- Cirrhotic NASH
- Discussion
